Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception.

Coordinator
Institut Gustave Roussy, France
Runs
1 December 2022 to 30 November 2027
Status
Running
EU funding
€7.0m
Total cost
€7.2m
Partners
13 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101095604

What the project is doing

In the project's own words, from its summary on CORDIS.

Cardiovascular disease (CVD) and lung cancer (LC) are leading causes of deaths and intertwined chronic inflammatory processes associated with metabolism reprogramming, clonal hematopoiesis of indeterminate potential (CHIP), intestinal dysbiosis, and maladaptive immunity. CVD prone-tobacco users exhibit a 1-2% yearly incidence of LC. Low dose computed tomography screening programs reduce LC mortality by 20%. Beyond epidemiological scores, risk identification, early cancer detection and interception are mostly based on cell autonomous approaches.

Understanding pathophysiological failures linking CVD to LC would allow to take steps for prevention. Based on metabolo-metageno-proteo-immuno-gen-omics, our PREVALUNG prospective study conducted in CVD tobacco consumers allowed to unveil four drivers of early carcinogenesis leading to actionable biomarkers that can be harnessed to pioneer personalized interceptive measures. Four main objectives will be harnessed by 7 academic partners (transdisciplinarity and trialists in interception), 3 diagnostic Biotech Cies and one nutrition Foundation.

First, refine and validate in retro- and pro-spective cohorts (>60.000), the 4 classifiers relying on the 4 inflammatory drivers (autophagy/innate immunity/intestinal barrier defects and CHIP) to implement patient stratification. Second, develop and validate robust friendly-user tools monitoring such biomarkers for routine risk assessment. Third, demonstrate the actionability of these biomarkers through a biologically-informed multi-arm randomised trial testing measures targeting each of the 4 main drivers of inflammation using food supplements or pharmacological agents (metformin, anti-NKG2A/PDL-1 Abs, IL-1 inhibitor, probiotics respectively) in addition to diet and life-style changes to return to homeostasis.

Fourth, to adapt a secured interface between patients and clinical researchers using these new tools to the longitudinal monitoring of the interceptive measures.

Topics

Who is involved

OrganisationCityCountryRole
Institut Gustave RoussyVillejuifFranceCoordinator
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Medical University Of VarnaVarnaBulgariaParticipant
Centre Hospitalier Regional De Marseille Assistance Publique-Hopitaux MarseilleMarseille Cedex 20FranceParticipant
Fondation Hopital Saint JosephParisFranceParticipant
Gustave Roussy TransfertVillejuifFranceThird party
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Patients En ReseauParisFranceParticipant
Universita Degli Studi Di TorinoTorinoItalyParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Bio-Me ASOsloNorwayParticipant
Olink Proteomics ABUppsalaSwedenParticipant
University College LondonLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI